HOVON HO147 MM

Open

Main info

Identificatie:
HO147 SMM
Sponsor:
HOVON
Working group party:
Myeloma
Age:
>= 18
Stadium:
1st lijn
Echelon:
Level C-HIC
Included patients:
33
(of 120)
Active sites:
8
(of 19)
9 sites are pending
Title:

Carfilzomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma: A Randomized Phase 2 Study.

Timeline

Scheduled
Actual
2018
21 jul.
EC Approval
2018
16 okt.
First Site
2018
17 dec.
Activated
2019
02 jan.
FPI
2024
02 jan.
ClosedForInclusionScheduledStart
2027
02 jan.
Endpoint Analysis
2029
02 jan.
Closeout in Progress
2030
02 jan.
Archived

News

Recently we sent out the approval for protocol v4.0.
There has been an unfortunate mistake, where the treatment days of Dexamethasone in Arm B (protocol page 20) have been removed. This is incorrect. Arm A and Arm B receive the same dosing of Dexamethasone on days 1, 2, 8, 9, 15, 16, 22 and 23.The correct treatment days are shown in the treatment schedule on page 4 of the protocol.

The following document has been updated:

  • Registration (and randomization) form_15-01-2019
  • Pharmacy info letter_02-05-2019

Details

Phase:
Prospective randomized Phase II study
Monitoring Type:
Study Specific
Objectives:

Primary objective:

  • The primary objective of the study is: to assess the progression-free survival rate of KRd versus Rd in patients with high-risk SMM

Secondary objectives:

  • To assess MRD status after 4 and 9 cycles induction treatment
  • To assess the correlation between PFS and MRD
  • To determine progression-free survival-2 (PFS2)
  • To determine duration of response (DOR)
  • To determine overall survival (OS)
  • To assess correlation of MRD status with PFS2, DOR and OS
  • To evaluate toxicity of combination therapy (carfilzomib, lenalidomide, and dexamethasone).
  • To evaluate disease heterogeneity in relation to clinical outcomes (molecular profiling on bone marrow samples)

Eligibility

Inclusion Criteria:
  • Patients must have histologically or cytologically confirmed Smoldering Multiple Myeloma based on the 2014 International Myeloma Working Group Criteria:
    • Serum M-protein ≥3.0 g/dl, or urinary monoclonal protein >500 mg per 24 hours, and/or monoclonal bone marrow plasma cells ≥10-60 %
    • Absence of CRAB symptoms:
      • anemia: Hemoglobin <6.2 mmol/L (10 g/dl) or a hemoglobin value of >1.2 mmol/L (2 g/dL) below the lower limit of normal
      • renal failure: serum creatinine > 2.0 mg/dL or creatinine clearance < 40 ml/min
      • hypercalcemia: serum calcium >0·25 mmol/L (>1 mg/dL) higher than the upper limit of normal or >2·75 mmol/L (>11 mg/dL)
      • Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET-CT
    • Absence of myeloma defining events:
      • Involved/uninvolved serum free light chain ratio ≥100 with involved free light-chain concentration ≥10 mg/dl
      • Presence of 2 or more focal lesions by MRI (2 of which at least 5 mm)
      • Clonal bone marrow plasma cell percentage ≥60%
  • Patients must have high risk Smoldering Multiple Myeloma based on the Mayo Clinic2 and/or the PETHEMA1 criteria:
    • 3 factors of Mayo Clinic criteria:
      • Bone marrow plasma cells ≥10 %
      • Serum M-protein ≥ 3 g/dl
      • Serum free light-chain ratio < 0.125 or > 8
    • And/Or 2 factors of PETHEMA criteria:
      • Of the plasma cell population ≥95% abnormal plasma cells (presence or absence of CD38, CD56, CD19 and/or CD45)
      • Immunoparesis, a reduction (below the lower normal limit) in the levels of 1 or 2 of the uninvolved immunoglobulins (Ig)
  • Measurable disease defined by any one of the following:
    • Serum monoclonal protein ≥ 1.0 g/dl
    • Urine monoclonal protein >200 mg/24 hour
    • Serum immunoglobulin free light chain >10 mg/dL AND abnormal kappa/lambda ratio (reference 0.26-1.65)
  • Age >18 years
  • WHO/ECOG performance status <2 (see Appendix C).
  • Patients must have normal organ and marrow function as defined below:
    • Absolute neutrophil count >1.0 x109 /L
    • Platelets ≥75 ×109 /L
    • Hemoglobin ≥10 g/dL (>6.2 mmol/l)
    • Total bilirubin <1.5 x institutional upper limit of normal
    • AST(SGOT)/ALT(SGPT) ≤3.0 × institutional upper limit of normal
  • Creatinine Clearance ≥ 50 ml/min. Creatinine clearance may be calculated using Cockcroft-Gault or eGFR (Modified Diet in Renal Disease [MDRD]). Detailed information regarding the different calculations are shown in protocol Appendix G.
  • Females of childbearing potential must have a negative serum or urine pregnancy test within 10 - 14 days prior to entry and again within 24 hours of starting lenalidomide treatment; (see 9.1.4 of protocol)
  • Patients must be willing and capable to use adequate contraception during and after the therapy (all men, all pre-menopausal women) (see 9.1.4. of protocol); Patients must be able to adhere to the requirements of the Lenalidomide Clinical Trial Pregnancy Prevention Plan;
  • Written informed consent
  • Patient is capable of giving informed consent
Exclusion Criteria:
  • Patients with symptomatic multiple myeloma (i.e. having myeloma defining events)
  • Amyloid Light-chain (AL) amyloidosis
  • Patients who are receiving any other investigational agents.
  • Concurrent systemic treatment or prior therapy within 4 weeks for SMM (if a patient has received any previous SMM therapy this must be discussed with the Principal Investigator before inclusion in the trial). Treatment with corticosteroids for other indications is permitted
  • Contraindication to any concomitant medication, including antivirals, anticoagulation prophylaxis, tumor lysis prophylaxis, or hydration given prior to therapy
  • History of allergic reactions attributed to immunomodulatory agents and proteasome inhibitors.
  • Uncontrolled hypertension or diabetes
  • Pregnant or lactating females.
  • Significant cardiovascular disease with NYHA grade III or IV symptoms, or hypertrophic cardiomegaly, or restrictive cardiomegaly, or myocardial infarction within 3 months prior to enrollment, or unstable angina, or unstable arrhythmia
  • Active hepatitis B or C infection
  • Known or suspected HIV infection
  • Incidence of gastrointestinal disease that would prevent absorption.
  • Significant neuropathy ≥Grade 3 or grade 2 with pain within 14 days of enrollment
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection.
  • History of other malignancy (apart from basal cell carcinoma of the skin, or in situ cervix carcinoma) except if the patient has been free of symptoms and without active therapy during at least 5 years
  • Major surgery within 1 month prior to enrollment
  • Pre-existing pulmonary, cardiac or renal impairement that prevents hydration measures as described at paragraph 9.1.4 of the protocol
  • Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule.

Registration Details

Eligible patients should be registered before start of treatment. Patients need to be registered at the HOVON Data Center by one of the following options:

  • By ALEA; select the [patient] tab and click the [ Add new patient] button. Complete all items and click the [Submit] button
  • By faxing the completed registration/randomization CRF +31.10.7041028 Monday through Friday, from 09:00 to 17:00 CET
  • By phone +31.10.7041560 Monday through Friday, from 09:00 to 17:00 CET

An Interim analysis is planned when 60 patients have been enrolled, and followed for a minimum of 1 year.

Participating Sites

Ziekenhuizen die deelnemen aan het onderzoek staan benoemd op de HOVON website bij het onderzoek. Het kan zijn dat uw ziekenhuis niet genoemd wordt, maar wel aan het onderzoek deelneemt. Informeer hiernaar bij uw arts.

Site
17 results
Order by
Accrual rate
Activation date
NO-Oslo-OSLOUH
18
22 nov. 2019
NL-Rotterdam-ERASMUSMC
10
16 okt. 2017
NL-Den Bosch-JBZ
4
29 jan. 2019
NL-Amsterdam-VUMC
1
19 mrt. 2019
CZ-Ostrava-Poruba-FNO
CZ-Brno-UHBRNO
NL-Sittard-Geleen-ZUYDERLAND
25 mei 2021
IT-Ancona-UMBERTOA
IT-Bologna-MALPHIGI
US-New York-MSKCC
IT-Torino-MOLINETTE
IT-Brescia-SPEDALICIVILI
NL-Leeuwarden-MCL
12 nov. 2019
NL-Hoofddorp-SPAARNEGASTHUIS
02 feb. 2021
NL-Utrecht-UMCUTRECHT
NL-Nijmegen-RADBOUDUMC
25 sep. 2019
IT-Roma-SAPIENZA
= Active hospitals
= Inactive hospitals

Participating Parties

Downloads

Up